BioCryst PharmaceuticalsBCRX
BCRX
About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Employees: 531
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
96% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $6.44M
51% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 35
21% more capital invested
Capital invested by funds: $1.09B [Q2] → $1.32B (+$225M) [Q3]
6% more funds holding
Funds holding: 240 [Q2] → 255 (+15) [Q3]
5% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 74
1.87% less ownership
Funds ownership: 85.61% [Q2] → 83.74% (-1.87%) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 4 (-2) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
7%
upside
Avg. target
$11.25
51%
upside
High target
$15
101%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Evercore ISI Group Liisa Bayko 50% 1-year accuracy 6 / 12 met price target | 61%upside $12 | Outperform Maintained | 13 Jan 2025 |
Needham Serge Belanger 36% 1-year accuracy 47 / 129 met price target | 101%upside $15 | Buy Maintained | 13 Jan 2025 |
RBC Capital Brian Abrahams 13% 1-year accuracy 10 / 79 met price target | 34%upside $10 | Outperform Reiterated | 5 Nov 2024 |
Barclays Gena Wang 16% 1-year accuracy 5 / 31 met price target | 7%upside $8 | Equal-Weight Maintained | 5 Nov 2024 |
Financial journalist opinion
Based on 3 articles about BCRX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB ® ) expected to be between $540-$560 million in 2025— —Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025— —New drug application planned in 2025 for ORLADEYO granules in children up to age 12; will address significant unmet need— —Pipeline advancing into patients with Netherton syndrome (BCX17725) and diabetic macular edema (avoralstat) in 2025— RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO® (berotralstat) net revenue and total revenue for the fourth quarter and full year 2024.
Neutral
GlobeNewsWire
2 weeks ago
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET.
Neutral
GlobeNewsWire
2 weeks ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 52,750 shares, and restricted stock units (RSUs) covering an aggregate of 36,975 shares, of BioCryst common stock. The options and RSUs were granted as of December 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
1 month ago
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
BioCryst remains a "Buy" due to ORLADEYO's proven success, potential growth, and management's confidence despite significant competition and a one-dimensional revenue stream. Q3 2024 showed mixed results with a modest revenue beat and slight earnings miss, leading to a 13% stock drop on higher volume. ORLADEYO's revenue guidance is strong, with expectations of reaching $1 billion annually by 2029, driven by its convenience and efficacy.
Neutral
GlobeNewsWire
1 month ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees stock options to purchase an aggregate of 17,400 shares, and restricted stock units (RSUs) covering an aggregate of 12,150 shares, of BioCryst common stock. The options and RSUs were granted as of November 29, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 months ago
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.
Neutral
GlobeNewsWire
2 months ago
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
Neutral
GlobeNewsWire
2 months ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees stock options to purchase an aggregate of 18,200 shares, and restricted stock units (RSUs) covering an aggregate of 12,750 shares, of BioCryst common stock. The options and RSUs were granted as of October 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
Seeking Alpha
2 months ago
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Jinky Rosselli - Chief Data and Insights Officer Conference Call Participants Nick Lenard - JPMorgan Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Maury Raycroft - Jefferies Stacy Ku - TD Cowen Liisa Bayko - Evercore ISI Gena Wang - Barclays Serge Belanger - Needham & Company Operator Good day and Welcome to the BioCryst Third Quarter 2024 Earnings Call. All participants will be in listen-only mode.
Neutral
Zacks Investment Research
2 months ago
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
Charts implemented using Lightweight Charts™